July 19, 2024 – Talk Bio

Actionable Insights Powered by AI

AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

9 months ago talkbio0Tagged AVEO, Fotivda, Malignant neoplasm of kidney, Neoplasms, nivolumab, Phase 3 Clinical Trials, Renal Cell Carcinoma, tivozanib

AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer

Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo

9 months ago talkbio0Tagged Accelerated, Agenus, Antineoplastic Agents, Approved, BOT, BOT/BAL, Colorectal Carcinoma, stock selloff, United States Food and Drug Administration

Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff

J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

9 months ago talkbio0Tagged Epilepsy, Johnson & Johnson, nervous system disorder, Phase 2 Clinical Trials, Receptors, Metabotropic Glutamate

Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders